CEO Corner
-
Our Long Journey To FDA Approval
9/1/2022
The financial markets, though, weren’t the cause of one of the most difficult periods I faced as CEO of AVEO Oncology. Instead, it was the decade-long journey we took to gain approval of our flagship kidney cancer drug, FOTIVDA (tivozanib), after significant regulatory and organizational setbacks.
-
How Diversity And Motherhood Fortified Me As A Women's Health CEO
8/1/2022
The lessons I have learned through my diverse background and motherhood are additive to those shared by many females who have stood up to share their perspectives and offer advice about how to break the pervasive glass ceiling.
-
Peeling Back The Layers Of The Digital Health Onion
8/1/2022
Digital health has radically changed patient care globally and disrupted healthcare, whilst also increasing speed and efficiency through new healthcare models.
-
5 Mistakes To Avoid When Scaling Your Biotech Startup
7/1/2022
My experiences have given me a deep well of expertise about the many factors that drive (or hinder) success as startups scale. Here are five traps founders must not fall victim to.
-
Why Russia's Invasion Of Ukraine Threatens Our Vibrant Life Science Ecosystem
6/1/2022
I posit that only pluralistic democracies committed to the rule of law can support the kind of investment and innovation our industry requires to thrive, while autocracies can’t make the same claim.
-
Recognizing The Value Of Biotech Partnerships In China
5/2/2022
China’s pharmaceutical market operates under regulations that are closely aligned with world standards, and the companies making innovative in-roads into the market are fueled by regional and international biotech finance.
-
An Intentionally Unconventional Journey To CEO
4/1/2022
I am glad to share my history here in hopes to spark a dialogue on how life science leaders are shaped, how contributions from “all paths” provide new perspectives, and how the benefits of nonconformity can improve future views — and functions therein — of leadership.
-
From CRO Executive To Biopharma CEO
3/1/2022
Taking over the CEO position of a biopharma in the midst of COVID, I was faced with many unique challenges. While I continue to work through these challenges, I’ve developed guidelines that have played a pivotal role in navigating such transitions.
-
The Key To Competitive Differentiation In Life Sciences Is People
2/1/2022
Especially in the early stage of a company, where speed and accuracy of drug development are highly valued, focusing on organizational strategies that provide differentiation enables a company to position itself as innovative.
-
What I Learned In A French Lab That Led To My Role As A CEO
2/1/2022
Our innovations didn’t happen overnight. From the very beginning, we knew that we would need to partner with others to be successful.